Communiqués bonyf NV

Actions

MLBON

BE6333353298

Temps réel Euronext Paris 17:55:00 07/09/2026			Varia. 5j.	Varia. 1 janv.
2,480 ^EUR	0,00%		0,00%	-49,39%

25/02	Bonyf, cotée à Paris, renonce à son projet de cotation au Nasdaq et engage des discussions pour des partenariats en Chine	MT
15/10/25	Bonyf NV obtient la certification européenne EU-MDR Classe IIa pour PerioCream	CI

Communiqués

31/08	Bonyf : EN PR bonyf enters a new era of “Renaissance” driven by its own brands and the international launch of PerioCream	PU
20/07	Bonyf : Confirms Strategic Transformation and Long-Term Growth Vision	PU
20/05	Bonyf : Annual General Meeting Date and Business Update	PU
24/04	Bonyf : Update on General Shareholders’ Meeting and Periocream Launch in Italy	PU
25/02	Bonyf : provides strategic update on PerioCream® commercial expansion and Nasdaq listing plans	PU
27/01	Bonyf : A Year of Certification, Innovation and Commercial Acceleration	PU
27/01	Bonyf : Une année de certification, d'innovation et d'accélération commerciale	PU
22/12	Bonyf : Mise à jour de la société sur la dynamique des marchés et les fondamentaux commerciaux	PU
22/12	Bonyf : Company Update on Market Trading Dynamics and Business Fundamentals	PU
24/11	Bonyf : PerioCream devient l'innovation bonyf la plus demandée	PU
24/11	Bonyf : PerioCream becomes the most in-demand bonyf innovation	PU
15/10/25	Bonyf AG receives the EU-MDR Certification Class IIa for PerioCream	EQ
15/09/25	Bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf	EQ
05/09/25	Bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments	EQ
11/08/25	Periocream: The Future Commercial Winner for bonyf	EQ
14/07/25	Bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility	EQ
30/06/25	Annual Results 2024	EQ
03/06/25	Bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India	EQ
15/05/25	Bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy	EQ
15/05/25	Bonyf : Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream	PU
08/04/25	Bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream	EQ
13/03/25	Bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne	EQ
18/02/25	Bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy	EQ
30/01/25	Bonyf R&D presents its two latest innovations at IDS 2025 in Cologne	EQ
10/12/24	Bonyf and Honest Pharma are pleased to announce a Strategic Alliance to bring revolutionary oral care products to the US market	EQ